Hematocrit: Drugs That Distort This Test and How to Interpret Results

What Hematocrit Actually Measures

Hematocrit (HCT) is the fraction of whole blood composed of red blood cells, expressed as a percentage. A standard complete blood count (CBC) calculates it by multiplying the mean corpuscular volume (MCV) by the red blood cell count. The result tells clinicians how efficiently your blood can carry oxygen and how viscous it may be at extremes 1.

The distinction matters clinically because hematocrit is a ratio, not an absolute count. Any process that changes plasma volume (dehydration, overhydration, or a drug that shifts fluid balance) will move hematocrit even if the total number of red blood cells stays the same. This is why a single elevated reading on testosterone replacement therapy does not always mean true polycythemia. It could reflect mild dehydration at the time of the draw 2.

Modern automated analyzers calculate hematocrit rather than measuring it by centrifugation, introducing slight methodological variance between laboratories. The American Association for Clinical Chemistry notes that calculated and spun hematocrit can differ by up to 1, 3 percentage points depending on the analyzer platform 3.

Normal Hematocrit Ranges and What Shifts Them

For adult men, most reference laboratories report a normal hematocrit of 38.3% to 48.6%. For adult women, the range is 35.5% to 44.9% 4. These values shift with altitude, age, hydration status, and pregnancy. Residents of high-altitude cities like Denver or Mexico City may run 2, 3 points higher than sea-level populations without any pathology present.

Age matters. Men over 70 show a gradual hematocrit decline of roughly 1, 2 percentage points per decade, which the Endocrine Society notes can mask early testosterone-induced erythrocytosis if pre-treatment baselines are not documented 5.

A value above 52% in men or 48% in women triggers a workup for polycythemia vera, secondary erythrocytosis, or drug-induced causes. A value below 36% in men or 33% in women usually prompts an anemia evaluation. But these cutoffs lose meaning if you do not account for what medications the patient is taking.

Drugs That Raise Hematocrit

Testosterone (All Formulations)

Testosterone replacement therapy is the single most common pharmacologic cause of elevated hematocrit in the outpatient setting. The Endocrine Society's 2018 Clinical Practice Guideline recommends checking hematocrit at baseline, at 3 to 6 months after initiation, and annually thereafter, with dose reduction or temporary cessation if hematocrit exceeds 54% 5.

The guideline states: "If hematocrit rises above 54%, stop testosterone therapy until hematocrit decreases to a safe level; reinitiate therapy at a reduced dose" 5.

How large is the effect? In a meta-analysis of 15 randomized controlled trials (N=2,029), testosterone therapy increased hematocrit by a weighted mean of 3.2 percentage points compared to placebo, with injectable formulations producing larger increases than transdermal gels 6. Testosterone cypionate 200 mg intramuscular every two weeks is the formulation most frequently associated with hematocrit readings above 54%, partly because supraphysiologic peaks occur 48 to 72 hours after injection 7.

Short-acting injections create the sharpest peaks. Subcutaneous testosterone, nasal testosterone (Natesto), and testosterone undecanoate (Aveed) produce more stable serum levels and appear to cause polycythemia less frequently, though head-to-head data remain limited 7.

Erythropoietin-Stimulating Agents (ESAs)

Epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) directly stimulate red blood cell production. They are prescribed for anemia of chronic kidney disease, chemotherapy-induced anemia, and select surgical settings. The FDA issued a black box warning after the CHOIR trial (N=1,432) showed that targeting hemoglobin above 13.5 g/dL (hematocrit roughly 40%) with epoetin alfa increased cardiovascular events and mortality in CKD patients compared to a target of 11.3 g/dL 8.

Current KDIGO guidelines recommend initiating ESAs when hemoglobin falls below 10 g/dL and not intentionally exceeding 11.5 g/dL 9. Patients on ESAs who present with hematocrit above 36% without a dose adjustment may be experiencing an overshoot that requires immediate dose reduction.

Anabolic Steroids Beyond TRT

Nandrolone decanoate (Deca-Durabolin), oxymetholone (Anadrol), and oxandrolone (Anavar) all stimulate erythropoiesis through androgen receptor activation in renal peritubular cells. Oxymetholone was originally FDA-approved specifically for aplastic anemia, where its erythropoietic potency is a therapeutic feature rather than a side effect. Bodybuilders and athletes who use supraphysiologic doses of stacked androgens can present with hematocrit values exceeding 58 to 60%, creating significant thrombotic risk 10.

Other Drugs That Raise Hematocrit

Several less obvious medications raise hematocrit through various mechanisms:

Diuretics. Thiazides and loop diuretics reduce plasma volume, concentrating red blood cells. This is a pseudoelevation. True red cell mass is unchanged. A patient on furosemide 40 mg daily who presents with a hematocrit of 52% may simply be volume-contracted 11.

Cobalt supplements. Cobalt chloride stabilizes hypoxia-inducible factor (HIF), mimicking altitude exposure and stimulating endogenous EPO production. It has been used as an illicit performance enhancer and is banned by the World Anti-Doping Agency 12.

HIF-prolyl hydroxylase inhibitors. Roxadustat (Evrenzo), daprodustat (Jesduvroq), and vadadustat are newer oral agents approved for CKD anemia in various markets. They raise hematocrit by stabilizing HIF and increasing endogenous erythropoietin production. Phase 3 data from the HIMALAYA trial program showed roxadustat increased hemoglobin by 1.8 to 2.0 g/dL over 24 weeks in dialysis-dependent CKD patients 13.

SGLT2 inhibitors. Empagliflozin and dapagliflozin cause hemoconcentration through osmotic diuresis and natriuresis. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin increased hematocrit by a mean of 2.8 percentage points at 12 weeks, an effect the investigators proposed as a possible mechanism behind the drug's cardiovascular mortality benefit 14.

Drugs That Lower Hematocrit

Myelosuppressive Chemotherapy

Cytotoxic drugs are the most powerful suppressors of hematocrit. Platinum-based regimens (cisplatin, carboplatin), alkylating agents (cyclophosphamide), and antimetabolites (methotrexate, 5-fluorouracil) all reduce red cell production by damaging hematopoietic progenitor cells in the bone marrow 15. Patients on active chemotherapy routinely drop their hematocrit by 5, 15 percentage points within the first two cycles.

Antiretroviral Agents

Zidovudine (AZT) is the classic offender, causing macrocytic anemia and hematocrit suppression through mitochondrial toxicity in erythroid precursors. Although zidovudine is now rarely used as first-line HIV therapy, it still appears in resource-limited settings. The Cochrane Collaboration documented anemia incidence of 5 to 10% with zidovudine-containing regimens versus 1 to 2% with tenofovir-based alternatives 16.

Immunosuppressants

Mycophenolate mofetil (CellCept) and azathioprine (Imuran) suppress hematocrit as part of their broader myelosuppressive profile. The American College of Rheumatology recommends CBC monitoring every 2 to 4 weeks during the first three months of azathioprine therapy 17.

GLP-1 Receptor Agonists

A less recognized effect: GLP-1 receptor agonists may mildly lower hematocrit. Pooled analysis of the SUSTAIN trial program for semaglutide showed a mean hemoglobin decrease of 0.3 to 0.5 g/dL over 30 to 56 weeks, translating to roughly a 1, 1.5 percentage point hematocrit drop 18. The mechanism is not fully characterized but may relate to plasma volume expansion or mild suppression of erythropoiesis. For patients co-prescribed testosterone and a GLP-1 agonist, this small offsetting effect may partially attenuate TRT-induced hematocrit rises, though no controlled trial has studied this combination specifically.

Other Suppressors

ACE inhibitors and ARBs. Enalapril, lisinopril, and losartan reduce erythropoietin production by decreasing angiotensin II-mediated EPO stimulation in the kidney. The AACE noted this effect in post-transplant erythrocytosis, where ACE inhibitors are used specifically to lower hematocrit 19.

Ribavirin. Used in hepatitis C treatment, ribavirin causes dose-dependent hemolytic anemia. Hematocrit drops of 8, 10 percentage points are common during the first 4 weeks of therapy 20.

NSAIDs and anticoagulants. These do not suppress production but can lower measured hematocrit through occult or overt GI blood loss. A patient on chronic aspirin plus warfarin with a hematocrit decline of 3, 5 points over 6 months warrants GI evaluation 21.

How Hydration and Timing Confound Results

Hematocrit is a ratio. Anything that changes the denominator (plasma volume) will shift the number. Dehydration from overnight fasting, intense exercise, or diuretic use can raise hematocrit by 2, 4 percentage points within hours. Overhydration from IV fluids can drop it by a similar margin 2.

For patients on testosterone therapy, timing relative to injection matters. Drawing blood 48 hours after an intramuscular testosterone cypionate injection captures the pharmacokinetic peak, when both testosterone and hematocrit are at their highest. The Endocrine Society recommends drawing midway between injections (trough or mid-cycle) for the most clinically representative value 5.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and contributor to the Endocrine Society guideline, has noted: "Clinicians should measure hematocrit at trough testosterone levels, not at peak, because peak-drawn values overestimate the patient's average erythrocytosis risk" 5.

Practical steps to reduce confounding:

• Draw fasting labs with normal hydration (8 oz of water permitted before the blood draw).
• For injectable TRT, schedule the draw the morning before the next scheduled injection.
• If hematocrit is borderline high (51 to 54%), repeat the test 2 to 4 weeks later before making dose changes.
• Document the exact time of last TRT dose in the lab order notes.

Clinical Decision Points: When to Act on Drug-Altered Hematocrit

Not every drug-induced hematocrit shift requires intervention. The clinical question is whether the altered value creates real risk or simply reflects expected pharmacology.

TRT patients with hematocrit 50 to 54%. Recheck in 4 to 8 weeks with confirmed hydration. If persistently above 52%, consider switching from IM injections to transdermal gel or subcutaneous injections to reduce peak-trough fluctuation. Therapeutic phlebotomy (removing 1 unit of blood) can acutely lower hematocrit by 3 percentage points and is a bridge while adjusting the testosterone dose 22.

TRT patients with hematocrit above 54%. The Endocrine Society guideline mandates testosterone cessation until hematocrit falls below 50%, followed by reinitiation at a reduced dose 5. Do not simply add phlebotomy and continue the same dose.

CKD patients on ESAs with hematocrit above 36%. Reduce the ESA dose by 25% and recheck in 2 to 4 weeks per KDIGO recommendations 9.

Patients on chemotherapy with hematocrit below 25%. Evaluate for transfusion. The AABB recommends a restrictive transfusion threshold of hemoglobin 7 g/dL (hematocrit roughly 21%) for hemodynamically stable hospitalized adults 23.

SGLT2 inhibitor users with rising hematocrit. This is expected pharmacology. Do not discontinue the SGLT2 inhibitor solely for a hematocrit increase of 2, 3 points unless the absolute value exceeds 54% in men or 48% in women.

Monitoring Schedules by Drug Class

The frequency of hematocrit monitoring depends on the offending drug and the patient's baseline:

• Testosterone (any formulation): baseline, 3 months, 6 months, then annually 5
• ESAs (epoetin, darbepoetin): every 1 to 2 weeks during dose titration, monthly once stable 9
• HIF-PHIs (roxadustat, daprodustat): every 2 weeks for the first month, then monthly 13
• Azathioprine / mycophenolate: every 2 to 4 weeks for 3 months, then every 3 months 17
• Chemotherapy regimens: before each cycle (typically every 2 to 3 weeks)
• Zidovudine-containing ART: at 4 weeks, 8 weeks, then every 3 months 16

Patients taking two or more drugs from the lists above should use the more frequent monitoring schedule of any single agent they are taking.